#None #Rhythm Biosciences #geneType #CancerIQ

CancerIQ Enhances Diagnostic Network with geneType™ Integration

CancerIQ, a leader in cancer-focused precision health solutions, has announced a significant expansion of its diagnostic network. The integration of the geneType™ Cancer Risk Assessment from Rhythm Biosciences into the CancerIQ platform is designed to elevate how healthcare providers assess and manage cancer risk across their patient populations.

This new assessment tool employs a polygenic risk score (PRS) combined with clinical data and family histories, providing crucial risk estimates over both five years and a lifetime for various cancer types. By harnessing diverse inputs, geneType™ strengthens risk evaluations beyond traditional models, pinpointing patients who might benefit from more tailored screening protocols.

The Importance of Comprehensive Risk Assessment

For individuals who have already undergone hereditary cancer testing or whose risk factors are not adequately captured by standard methods, geneType™ presents a pivotal next step. It offers deeper insights that can guide clinical decision-making, promoting early detection and personalized care. CancerIQ’s platform is designed to assist patients thoroughly throughout the genetic testing journey, incorporating testing into routine care with seamless integrations.

Feyi Ayodele, CancerIQ's CEO and Co-founder, expressed enthusiasm about the partnership, stating, "We are pleased to collaborate with Rhythm Biosciences to introduce geneType™ through the CancerIQ platform. This addition broadens the diagnostic tools accessible to providers, ensuring that critical awareness occurs at the point of care."

Rhythm Biosciences' Dr. David Atkins, CEO and Managing Director, echoed this sentiment, highlighting the company’s enthusiastic participation in a network that connects right patients with the right diagnostic tools in real-time across 60+ health systems.

A Broader Vision for Cancer Screening

CancerIQ is committed to expanding its array of diagnostic partnerships, addressing genetic testing, imaging, liquid biopsy, and multi-cancer early detection. This commitment is vital for integrating innovative technologies within existing cancer treatment frameworks, ensuring that advancements reach patients efficiently.

About Rhythm Biosciences

Headquartered in Melbourne, Australia, Rhythm Biosciences is an innovative medical diagnostics firm created to provide straightforward, affordable blood tests for the early and accurate detection of cancer. Established in 2017, Rhythm focuses on enhancing patient outcomes by facilitating detection at the earliest stages of illness, ultimately aiming to reduce the global impact of cancer. More information is available at rhythmbio.com.

Advancements in Genetic Risk Assessment

The geneType™ platform combines various forms of data—clinical, familial, and genetic—to deliver extensive assessments for multiple diseases, including prevalent conditions like breast cancer, diabetes, cardiovascular diseases, and melanoma. This multifaceted approach provides personalized health insights, allowing for more informed medical decisions. By ensuring optimal clinical oversight during the testing procedure, patients receive reliable and useful results.

As the healthcare landscape continues to evolve towards preventative care and precision medicine, tools like geneType™ will likely play a crucial role in addressing the growing need for specialized cancer screening and assessment solutions. By providing practitioners with the necessary resources for effective risk evaluation, CancerIQ and Rhythm Biosciences are poised to make noteworthy impacts on cancer prevention and treatment strategies.